Ovatodiolide Formulation for HPV-Positive Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for papillomavirus-associated diseases, such as cervical and head and neck cancers, often have toxic side effects and lack effective agents that specifically target HPV-positive cells, with a need for more potent and less toxic therapies.
Innovation Solution
Ovatodiolide, isolated from Anisomeles malabarica, Anisomeles indica, and Anisomeles ovata, exhibits apoptosis-inducing properties and inhibits E6 and E7 protein expression, offering a novel mechanism to treat HPV-positive cancers and papillomavirus-mediated diseases, including warts, through pharmaceutical compositions and emulsions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard therapy (cisplatin and radiation) is used to treat head and neck cancer, then cancer treatment efficacy is improved, but toxic side effects increase
Solution Approach 1:
The patent extracts and utilizes Ovatodiolide, a specific active compound from Anisomeles malabarica plant, to replace the toxic cisplatin chemotherapy regimen. This extraction of the essential therapeutic agent from the plant material provides cancer treatment efficacy while eliminating the severe toxic side effects associated with conventional chemotherapy drugs.
Solution Approach 2:
The patent employs a natural plant-based compound (Ovatodiolide) that can be replenished through continuous plant cultivation, replacing the need for expensive and highly toxic synthetic chemotherapy agents. The plant material serves as a renewable, sustainable source of therapeutic compounds.
2Reliability
If Ovatodiolide is used to induce apoptosis in HPV-positive cells, then potency and specificity are improved, but selectivity against primary cells must be maintained
Solution Approach 1:
The patent achieves local quality by making Ovatodiolide's apoptotic effect specific to HPV-positive cancer cells through the mechanism of inhibiting E6 and E7 oncoprotein expression. The compound selectively targets cells with HPV infection while sparing primary cells that lack these viral proteins, thereby achieving high potency with minimal harm to healthy tissues.
Solution Approach 2:
The patent uses the viral E6 and E7 oncoproteins as intermediaries that mediate the selective toxicity of Ovatodiolide. By targeting these viral proteins that are only present in HPV-positive cells, the compound achieves selective apoptosis induction. The viral proteins serve as the intermediary target that enables specificity between cancerous and healthy cells.
Data Source
AI summary
A pharmaceutical composition for anti-viral treatment for papillomavirus associated diseases in mammals, comprising a therapeutically effective amount of Ovatodiolide or Ovatodiolide related substances or an enriched plant extract containing anisomelic acid and ovatiodiolide. The pharmaceutical composition may comprise Ovatodiolide or Ovatodiolide related substances or the enriched extract in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvent or surfactant or a combination thereof. A method of treating or preventing papillomavirus associated diseases in a mammal is also provided.